These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 28248151)
21. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Bartlett R; Stokes L; Sluyter R Pharmacol Rev; 2014 Jul; 66(3):638-75. PubMed ID: 24928329 [TBL] [Abstract][Full Text] [Related]
22. The therapeutic potential of purinergic signalling. Burnstock G Biochem Pharmacol; 2018 May; 151():157-165. PubMed ID: 28735873 [TBL] [Abstract][Full Text] [Related]
23. Purinergic Signalling and Neurological Diseases: An Update. Burnstock G CNS Neurol Disord Drug Targets; 2017; 16(3):257-265. PubMed ID: 27658510 [TBL] [Abstract][Full Text] [Related]
25. A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334. Lord B; Ameriks MK; Wang Q; Fourgeaud L; Vliegen M; Verluyten W; Haspeslagh P; Carruthers NI; Lovenberg TW; Bonaventure P; Letavic MA; Bhattacharya A Eur J Pharmacol; 2015 Oct; 765():551-9. PubMed ID: 26386289 [TBL] [Abstract][Full Text] [Related]
26. Role of the purinergic P2X receptors in osteoclast pathophysiology. Jørgensen NR Curr Opin Pharmacol; 2019 Aug; 47():97-101. PubMed ID: 30954934 [TBL] [Abstract][Full Text] [Related]
27. Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Rudolph DA; Alcazar J; Ameriks MK; Anton AB; Ao H; Bonaventure P; Carruthers NI; Chrovian CC; De Angelis M; Lord B; Rech JC; Wang Q; Bhattacharya A; Andres JI; Letavic MA Bioorg Med Chem Lett; 2015 Aug; 25(16):3157-63. PubMed ID: 26099534 [TBL] [Abstract][Full Text] [Related]
28. The role of P2X7 receptors in tissue fibrosis: a brief review. Gentile D; Natale M; Lazzerini PE; Capecchi PL; Laghi-Pasini F Purinergic Signal; 2015 Dec; 11(4):435-40. PubMed ID: 26318434 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 2. Brumfield S; Matasi JJ; Tulshian D; Czarniecki M; Greenlee W; Garlisi C; Qiu H; Devito K; Chen SC; Sun Y; Bertorelli R; Ansell J; Geiss W; Le VD; Martin GS; Vellekoop SA; Haber J; Allard ML Bioorg Med Chem Lett; 2011 Dec; 21(24):7287-90. PubMed ID: 22078214 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and SAR development of quinoline analogs as novel P2X7 receptor antagonists. Xiao Y; Karra S; Goutopoulos A; Morse NT; Zhang S; Dhanabal M; Tian H; Seenisamy J; Jayadevan J; Caldwell R; Potnick J; Bleich M; Chekler E; Sherer B; Sriraman V Bioorg Med Chem Lett; 2019 Jul; 29(13):1660-1664. PubMed ID: 31031055 [TBL] [Abstract][Full Text] [Related]
33. Tanshinone II A sulfonate, but not tanshinone II A, acts as potent negative allosteric modulator of the human purinergic receptor P2X7. Kaiser M; Sobottka H; Fischer W; Schaefer M; Nörenberg W J Pharmacol Exp Ther; 2014 Sep; 350(3):531-42. PubMed ID: 24970925 [TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationships and optimization of 3,5-dichloropyridine derivatives as novel P2X(7) receptor antagonists. Lee WG; Lee SD; Cho JH; Jung Y; Kim JH; Hien TT; Kang KW; Ko H; Kim YC J Med Chem; 2012 Apr; 55(8):3687-98. PubMed ID: 22400713 [TBL] [Abstract][Full Text] [Related]
35. Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists. Patberg M; Isaak A; Füsser F; Ortiz Zacarías NV; Vinnenberg L; Schulte J; Michetti L; Grey L; van der Horst C; Hundehege P; Koch O; Heitman LH; Budde T; Junker A Eur J Med Chem; 2021 Dec; 226():113838. PubMed ID: 34571173 [TBL] [Abstract][Full Text] [Related]
36. P2X7 receptor antagonism in the treatment of cancers. Roger S; Pelegrin P Expert Opin Investig Drugs; 2011 Jul; 20(7):875-80. PubMed ID: 21619470 [TBL] [Abstract][Full Text] [Related]
37. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor. Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M Neuropharmacology; 2013 Dec; 75():365-79. PubMed ID: 23954492 [TBL] [Abstract][Full Text] [Related]
38. P2X7 receptors at adult neural progenitor cells of the mouse subventricular zone. Messemer N; Kunert C; Grohmann M; Sobottka H; Nieber K; Zimmermann H; Franke H; Nörenberg W; Straub I; Schaefer M; Riedel T; Illes P; Rubini P Neuropharmacology; 2013 Oct; 73():122-37. PubMed ID: 23727220 [TBL] [Abstract][Full Text] [Related]
39. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages. Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059 [TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists. Park JH; Lee GE; Lee SD; Ko H; Kim YC Eur J Med Chem; 2015 Dec; 106():180-93. PubMed ID: 26547056 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]